go back

Brexucabtagene Autoleucel (Tecartus) CAR-T Therapy

New Mexico rates for HCPCS Q2053

Brexucabtagene autoleucel, up to 200 million autologous anti-CD19 CAR positive viable T cells, including leukapheresis and dose preparation procedures, per therapeutic dose

Rates data updated July 2026.

Facilitymedian $537,032 · 10th–90th $489,779$812,8310%50%10th90th$537,032Professionalmedian $489,779 · 10th–90th $489,779$616,5950%50%90th$489,779$0.1$1.0$20.0$500.0$10.0K$200.0K

Distribution of negotiated rates across all payers (price axis is log-scale). Facility and professional rates are different services and are charted separately. Need provider-level prices? Contact us.

Insurance Carrier
Aetna
Setting
Facility
Modifier
Global
Typical Low
$537,031.80
Median
$758,577.58
Typical High
$1,412,537.54
Aetna
Setting
Professional
Modifier
Global
Typical Low
$489,778.82
Median
$489,778.82
Typical High
$616,595.00
Molina
Setting
Professional
Modifier
Global
Typical Low
$562,341.33
Median
$562,341.33
Typical High
$1,047,128.55
Providence
Setting
Facility
Modifier
Global
Typical Low
$489,778.82
Median
$537,031.80
Typical High
$812,830.52
Providence
Setting
Professional
Modifier
Global
Typical Low
$588,843.66
Median
$616,595.00
Typical High
$758,577.58
United
Setting
Facility
Modifier
Global
Typical Low
$489,778.82
Median
$489,778.82
Typical High
$812,830.52
United
Setting
Professional
Modifier
Global
Typical Low
$363,078.05
Median
$467,735.14
Typical High
$1,071,519.31